Free Trial
NASDAQ:RNA

Avidity Biosciences Q3 2023 Earnings Report

Avidity Biosciences logo
$32.28 +0.08 (+0.25%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$30.00 -2.28 (-7.06%)
As of 05:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avidity Biosciences EPS Results

Actual EPS
-$0.71
Consensus EPS
-$0.76
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Avidity Biosciences Revenue Results

Actual Revenue
$2.82 million
Expected Revenue
$2.09 million
Beat/Miss
Beat by +$730.00 thousand
YoY Revenue Growth
N/A

Avidity Biosciences Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Wednesday, November 8, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Avidity Biosciences' Q1 2025 earnings is scheduled for Thursday, May 8, 2025

Avidity Biosciences Earnings Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Avidity Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avidity Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avidity Biosciences and other key companies, straight to your email.

About Avidity Biosciences

Avidity Biosciences (NASDAQ:RNA), a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

View Avidity Biosciences Profile

More Earnings Resources from MarketBeat